Key facts
- Judo Bio’s last known valuation is $115.0M.
- It has raised $105.0M across 3 recorded rounds; the latest was Early Stage VC ($25.0M) in Jul 2024.
- Notable investors include Alexandria Venture Investments, Digitalis Ventures, Euclidean Capital, Atlas Venture, Droia Ventures — 7 tracked in total.
- Judo Bio has filed 4 Form Ds with the SEC since 2022, most recently Aug 2024 ($25.0M sold to 21 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Judo Bio
Funding rounds
3 roundsAbout Judo Bio
Developer of oligonucleotide therapies intended to offer genetic medicines. The company helps to pair the gene-silencing nucleic acid with a targeting molecule to specific types of kidney cells, enabling healthcare professionals to treat systemic and renal diseases.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 4
- Website
- judo.bio/
- Ownership
- Privately Held (backing)
Judo Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Judo Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Judo Bio in its N-PORT filings yet. We sweep new filings monthly.